Furosemide vs. Placebo for Severe Antepartum Hypertension
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Primary objective: To determine whether the addition of intravenous furosemide with usual
antihypertensives is associated with a reduction in mean systolic blood pressure from
baseline compared to treatment with placebo plus usual antihypertensives (intravenous
labetalol, intravenous hydralazine, or oral immediate release nifedipine) for the management
of severe antepartum hypertension.
Secondary objectives:
To determine whether the addition of intravenous furosemide with usual antihypertensives is
associated with a reduction in mean diastolic blood pressure compared to treatment with
placebo plus usual antihypertensives listed above.